UNSPSC 51313107: Oxatomide

This classification denotes a histamine-1 receptor antagonist with the molecular formula C27H30N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J31IL9Z2EE, chemically known as 2h-benzimidazol-2-one, 1,3-dihydro-1-(3-(4-(diphenylmethyl)-1-piperazinyl)propyl)- but generally known as oxatomide, which bears US NIH Compound Identifier 4615. European Medicines Agency schedules Oxatomide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09504MIG.

UNSPSC 51313107 Oxatomide, a Commodity code, does not appear to align with the recent state and local procurement activity tagged under it. The single available opportunity — Seminole County, Florida's IFB 60459723LAS — solicits naloxone and safe drug deactivation systems, neither of which are oxatomide, an antihistamine pharmaceutical used in clinical settings. The mismatch suggests either a miscoding in the county's procurement system or a divergence between the code's nominal pharmaceutical scope and how the jurisdiction has applied it.

The Seminole County opportunity, posted June 30, 2026 with a response deadline of July 26, 2023, calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford. The procurement requires electronic bid submission, vendor drug-free workplace certification, E-Verify compliance, and proof of insurance including workers' compensation and commercial general liability coverage. The contract runs two years with an optional one-year renewal and includes a three-month probationary termination clause. The county notes potential FEMA funding and associated federal compliance obligations. Given the absence of additional recent opportunities under this code and the categorical mismatch of the single available record, activity under UNSPSC 51313107 does not currently reflect a coherent procurement signal for oxatomide or closely related pharmaceutical commodities at the state and local level.